About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
  > MEDIA
  Overview
  Press Releases
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts
  
  
     
 
Press Releases

Biocon's Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity

Bengaluru, India: August 22, 2019:

Biocon Ltd (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceuticals company, announced today that its subsidiary in Malaysia, Biocon Sdn. Bhd., which operates Asia's largest integrated Insulins facility, received the Certificate of GMP compliance from the European Medicines Agency from the representative European inspection authority, Health Products Regulatory Authority (Ireland). This approval expands Biocon’s capacities multi-fold with the new large scale devices facility coming up to speed to serve the growing needs of people with diabetes in EU.

The Malaysia site was inspected in May 2019 and the certificate of GMP compliance received now reflects that the agency considers the manufacturing facilities for Drug Substances, Drug Products and Insulin Delivery Devices to be in compliance with the guidelines of Good Manufacturing Practices. Biocon remains committed to highest global standards of Quality and Compliance.

Biocon’s Malaysia facility is Asia's largest integrated insulins facility and manufactures Drug Substance and Drug Products in vials, cartridges and insulin delivery devices

The recombinant human Insulin (rh-Insulin) and Insulin Glargine manufactured at this facility are addressing the needs of over 350,000 diabetic patients in Malaysia. Biocon and Mylan’s Biosimilar Insulin Glargine Semglee® has previously received Regulatory approval from EMA in March 2018 and has been launched in key European markets by its partner Mylan since Nov 2018.

Biocon has emerged as a leading insulins player globally. The Company has the science, scale, scope, technology and over 15 years of experience in addressing the needs of patients with diabetes, having provided over 2 billion doses of insulins cumulatively, worldwide.

Our range of insulins made at the state-of-the-art Malaysia facility are serving patient populations in EU and several other countries across the globe.

Biocon's rh-Insulin is registered in over 40 countries worldwide and has been commercialized in many emerging markets. The Company’s biosimilar Insulin Glargine has been approved in over 60 countries and is commercialized in several key emerging markets.

Biocon through its biosimilars portfolio is committed to serve the needs of patients, people & partners by providing innovative affordable healthcare solutions going beyond the product. Biocon's Biologics Business started FY20 on a very strong note with a robust revenue growth of 96% at Rs 490 Cr in Q1FY20. This Business aims to impact 2.6 million patient lives in FY20 and aspires to position the company as a global leader.

About Biocon Ltd:
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is a fully integrated, innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune diseases. The Company has developed and commercialized a range of Biosimilars (Monoclonal Antibodies, Pegfilgrastim, rh- Insulin and Insulin Glargine), Novel Biologics and differentiated Small Molecules in India and key emerging markets. It has a large portfolio of biosimilars under global clinical development with three of these commercialized in the developed markets of EU, U.S. and Japan. It has promising novel assets in immunotherapy under development. Some of its key brands are INSUGEN® (rh-insulin), Basalog One® (prefilled Glargine pen), CANMAb™ (Trastuzumab), KRABEVA® (Bevacizumab), BIOMAb-EGFR® (Nimotuzumab) and ALZUMAb™ (Itolizumab).
www.biocon.com Follow-us on Twitter: @bioconlimited


BIOCON
Seema Ahuja (Media)
Sr. VP & Global Head, Corporate Communications
+91 80 2808 2222, M:+91 99723 17792
Email: seema.ahuja@biocon.com
INVESTOR RELATIONS Saurabh Paliwal
Head, Investor Relations
+91 80 6775 2040, M:+91 95383 80801
Email: investor.relations@biocon.com
<< Back

 

 Download Press Release
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved